SARS-CoV-2 변이주 (Korean Wikipedia)
Analysis of information sources in references of the Wikipedia article "SARS-CoV-2 변이주" in Korean language version.
refsWebsite
Global rank
Korean rank
low place
low place
1,877th place
low place
1st place
1st place
low place
low place
5th place
11th place
640th place
2,040th place
low place
low place
low place
low place
low place
low place
234th place
148th place
11th place
310th place
857th place
295th place
12th place
65th place
30th place
129th place
383rd place
118th place
140th place
251st place
7,025th place
3,399th place
businessinsider.com
- “A coronavirus variant with a mutation that 'likely helps it escape' antibodies is already in at least 11 countries, including the US”. Business Insider. 2021년 2월 16일. 2021년 2월 16일에 확인함.
cdc.gov
- “SARS-CoV-2 Variant Classifications and Definitions”. 《CDC.gov》. Centers for Disease Control and Prevention.
- “Emerging SARS-CoV-2 Variants”. 《CDC.gov》 (Science brief). Centers for Disease Control and Prevention. 2021년 1월 28일. 2021년 1월 4일에 확인함.
이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다. - “SARS-CoV-2 Variant Classifications and Definitions”. 《CDC.gov》. Centers for Disease Control and Prevention. 2021년 5월 12일. 2021년 5월 16일에 확인함.
cnn.com
edition.cnn.com
- Azad, Arman (2021년 3월 17일). “Coronavirus strains first detected in California are officially 'variants of concern,' CDC says”. 《CNN》. 2021년 6월 6일에 확인함.
cov-lineages.org
- “Lineage descriptions”. 《cov-lineages.org》. Pango team.
- “B.1.525 international lineage report”. 《cov-lineages.org》. Pango team. 2021년 6월 4일에 확인함.
- “B.1.525”. 《cov-lineages.org》. Pango team. 2021년 3월 22일에 확인함.
- “B.1.525”. 《cov-lineages.org》. Pango team. 2021년 3월 22일에 확인함.
doi.org
dx.doi.org
- Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD; 외. (2021). “Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.”. 《Science》 372 (6538). doi:10.1126/science.abg3055. PMC 8128288. PMID 33658326.
- Davies G, Jarvis C, Edmunds WJ, Jewell N, Diaz-Ordaz K, Keogh R (2021년 3월 15일). “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. 《Nature》 (Published) 593 (7858): 270–274. doi:10.1038/s41586-021-03426-1. PMID 33723411. 2021년 4월 29일에 확인함.
- DChallen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L (2021년 3월 10일). “Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study”. 《The BMJ》 (Published) 372: n579. doi:10.1136/bmj.n579. PMC 7941603. PMID 33687922.
- Planas D, Bruel T, Grzelak L, 외. (2021년 4월 14일). “Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies”. 《Nature Medicine》 27 (5): 917–924. doi:10.1038/s41591-021-01318-5. PMID 33772244.
- Coutinho RM, Marquitti FM, Ferreira LS, Borges ME, da Silva RL, Canton O, 외. (2021년 3월 23일). “Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant”. 《medRxiv》 (Preprint): 9. doi:10.1101/2021.03.03.21252706. S2CID 232119656. 2021년 4월 29일에 확인함.
The new variant was found to be about 2.6 times more transmissible (95% Confidence Interval (CI): 2.4–2.8) than previous circulating variant(s). ... Table 1: Summary of the fitted parameters and respective confidence intervals considering the entire period, November 1, 2020-January 31, 2021 maintaining the same pathogenicity of the previous variant. Parameter: Relative transmission rate for the new variant. Estimate: 2.61. 2.5%: 2.45. 97.5%: 2.76.
- Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DS, Mishra S, 외. (2021년 5월 21일). “Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil”. 《Science》 372 (6544): 815–821. doi:10.1126/science.abh2644. ISSN 0036-8075. PMC 8139423. PMID 33853970.
Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city’s health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
- Freitas AR, Lemos DR, Beckedorff OA, Cavalcanti LP, Siqueira AM, Mello RC, 외. (2021년 4월 19일). “The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions” (Preprint). doi:10.1101/2021.04.13.21255281 – medRxiv 경유.
Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95% CI, 2.9-11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95% CI, 5.01-11.83; p <0.0001) comparing with November–December. ... The heterogeneity observed between the age groups was greater when we analyzed the subgroup of the population without preexisting risk conditions where we found that the CFR in the female sex in the second wave was 1.95 times (95% CI, 1.38-2.76) the CFR of the first wave in the population over 85 years old and was 7.7 times (95% CI, 5.01-11.83; p < 0.0001) in the population between 40 and 59 years old. In the male population without previous diseases, the CFR in the second wave was 2.18 (95% CI, 1.62-2.93) times the CFR of the first wave in the population over 85 years old and 5.9 (95% CI, 3.2-10.85; p < 0, 0001) higher in the range between 20 and 39 years old.
- Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, 외. (March 2021). “Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation”. 《MedRxiv》 (Preprint). doi:10.1101/2021.03.07.21252647. PMC 7987058. PMID 33758899.
- Wadman M (2021년 2월 23일). “California coronavirus strain may be more infectious – and lethal”. 《Science News》. doi:10.1126/science.abh2101. 2021년 3월 17일에 확인함.
- Sheikh A, McMenamin J, Taylor B, Robertson C (June 2021). “SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness”. 《Lancet》 397 (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.
- Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, 외. (2021년 5월 7일). “Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees.”. 《Clinical Infectious Diseases》 (Oxford University Press). bioRxiv 10.1101/2021.04.23.441101
|biorxiv=값 확인 필요 (도움말). doi:10.1093/cid/ciab411. PMID 33961693. - Ferguson N, Ghani A, Hinsley W, Volz E (2021년 12월 22일). 《Hospitalisation risk for Omicron cases in England》 (PDF) (기술 보고서). WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis. Imperial College London. doi:10.25561/93035. Report 50. 2021년 12월 23일에 원본 문서에서 보존된 문서.
doi.org
- Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, 외. (2021년 5월 7일). “Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees.”. 《Clinical Infectious Diseases》 (Oxford University Press). bioRxiv 10.1101/2021.04.23.441101
|biorxiv=값 확인 필요 (도움말). doi:10.1093/cid/ciab411. PMID 33961693.
europa.eu
ecdc.europa.eu
- “SARS-CoV-2 variants of concern”. 《ECDC.eu》. European Centre for Disease Prevention and Control. 2021년 6월 7일에 확인함.
- 《Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update》 (Risk assessment). European Centre for Disease Prevention and Control. 2021년 2월 2일.
github.com
- “Date mismatch between international report and lineage description - cov-lineages/pangolin”. 《GitHub》 (Software issue). 2021년 6월 13일. 2021년 6월 14일에 확인함.
gov.uk
- “Variants: distribution of cases data”. 《GOV.UK》. Government Digital Service. Public Health England.
- “Investigation of SARS-CoV-2 variants of concern: technical briefings”. 《GOV.UK》. Government Digital Service. Public Health England.
- Horby, Peter; Barclay, Wendy; Huntley, Catherine (2021년 1월 13일). 《NERVTAG paper: brief note on SARS-CoV-2 variants》 (Note). Public Health England. 2021년 6월 6일에 확인함.
- “Confirmed cases of COVID-19 variants identified in UK”. Friday 15 January: GOV.UK. Public Health England. 2021년 1월 15일.
- Horby, Peter; Barclay, Wendy; Gupta, Ravi; Huntley, Catherine (2021년 1월 27일). 《NERVTAG paper: note on variant P.1》 (Note). Public Health England. 2021년 6월 6일에 확인함.
imperial.ac.uk
- Ferguson N, Ghani A, Hinsley W, Volz E (2021년 12월 22일). 《Hospitalisation risk for Omicron cases in England》 (PDF) (기술 보고서). WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis. Imperial College London. doi:10.25561/93035. Report 50. 2021년 12월 23일에 원본 문서에서 보존된 문서.
medrxiv.org
- Coutinho RM, Marquitti FM, Ferreira LS, Borges ME, da Silva RL, Canton O, 외. (2021년 3월 23일). “Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant”. 《medRxiv》 (Preprint): 9. doi:10.1101/2021.03.03.21252706. S2CID 232119656. 2021년 4월 29일에 확인함.
The new variant was found to be about 2.6 times more transmissible (95% Confidence Interval (CI): 2.4–2.8) than previous circulating variant(s). ... Table 1: Summary of the fitted parameters and respective confidence intervals considering the entire period, November 1, 2020-January 31, 2021 maintaining the same pathogenicity of the previous variant. Parameter: Relative transmission rate for the new variant. Estimate: 2.61. 2.5%: 2.45. 97.5%: 2.76.
- Freitas AR, Lemos DR, Beckedorff OA, Cavalcanti LP, Siqueira AM, Mello RC, 외. (2021년 4월 19일). “The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions” (Preprint). doi:10.1101/2021.04.13.21255281 – medRxiv 경유.
Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95% CI, 2.9-11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95% CI, 5.01-11.83; p <0.0001) comparing with November–December. ... The heterogeneity observed between the age groups was greater when we analyzed the subgroup of the population without preexisting risk conditions where we found that the CFR in the female sex in the second wave was 1.95 times (95% CI, 1.38-2.76) the CFR of the first wave in the population over 85 years old and was 7.7 times (95% CI, 5.01-11.83; p < 0.0001) in the population between 40 and 59 years old. In the male population without previous diseases, the CFR in the second wave was 2.18 (95% CI, 1.62-2.93) times the CFR of the first wave in the population over 85 years old and 5.9 (95% CI, 3.2-10.85; p < 0, 0001) higher in the range between 20 and 39 years old.
mt.co.kr
news.mt.co.kr
- https://news.mt.co.kr/mtview.php?no=2021081314552057045.
|제목=이(가) 없거나 비었음 (도움말)
nature.com
- Davies G, Jarvis C, Edmunds WJ, Jewell N, Diaz-Ordaz K, Keogh R (2021년 3월 15일). “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. 《Nature》 (Published) 593 (7858): 270–274. doi:10.1038/s41586-021-03426-1. PMID 33723411. 2021년 4월 29일에 확인함.
nextstrain.org
- “Nextstrain”. 《nextstrain.org》. Nextstrain.
nih.gov
ncbi.nlm.nih.gov
- Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD; 외. (2021). “Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.”. 《Science》 372 (6538). doi:10.1126/science.abg3055. PMC 8128288. PMID 33658326.
- Davies G, Jarvis C, Edmunds WJ, Jewell N, Diaz-Ordaz K, Keogh R (2021년 3월 15일). “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. 《Nature》 (Published) 593 (7858): 270–274. doi:10.1038/s41586-021-03426-1. PMID 33723411. 2021년 4월 29일에 확인함.
- DChallen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L (2021년 3월 10일). “Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study”. 《The BMJ》 (Published) 372: n579. doi:10.1136/bmj.n579. PMC 7941603. PMID 33687922.
- Planas D, Bruel T, Grzelak L, 외. (2021년 4월 14일). “Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies”. 《Nature Medicine》 27 (5): 917–924. doi:10.1038/s41591-021-01318-5. PMID 33772244.
- Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DS, Mishra S, 외. (2021년 5월 21일). “Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil”. 《Science》 372 (6544): 815–821. doi:10.1126/science.abh2644. ISSN 0036-8075. PMC 8139423. PMID 33853970.
Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city’s health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
- Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, 외. (March 2021). “Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation”. 《MedRxiv》 (Preprint). doi:10.1101/2021.03.07.21252647. PMC 7987058. PMID 33758899.
- Sheikh A, McMenamin J, Taylor B, Robertson C (June 2021). “SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness”. 《Lancet》 397 (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.
- Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, 외. (2021년 5월 7일). “Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees.”. 《Clinical Infectious Diseases》 (Oxford University Press). bioRxiv 10.1101/2021.04.23.441101
|biorxiv=값 확인 필요 (도움말). doi:10.1093/cid/ciab411. PMID 33961693.
nsw.gov.au
aci.health.nsw.gov.au
- “Living Evidence – SARS-CoV-2 variants”. Agency for Clinical Innovation. 《nsw.gov.au》. Ministry of Health (New South Wales). 2021년 4월 16일에 원본 문서에서 보존된 문서. 2021년 3월 22일에 확인함.
oup.com
academic.oup.com
- Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, 외. (2021년 5월 7일). “Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees.”. 《Clinical Infectious Diseases》 (Oxford University Press). bioRxiv 10.1101/2021.04.23.441101
|biorxiv=값 확인 필요 (도움말). doi:10.1093/cid/ciab411. PMID 33961693.
publishing.service.gov.uk
assets.publishing.service.gov.uk
- 《Investigation of novel SARS-COV-2 variant, technical briefing 1》 (PDF) (Briefing). Public Health England. 2020년 12월 21일. 2021년 6월 6일에 확인함.
- 《SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 10》 (PDF) (Briefing). Public Health England. 2021년 5월 7일. GOV-8226. 2021년 6월 6일에 확인함.
- “SARS-CoV-2 variants of concern and variants under investigation in England Technical Briefing 21” (PDF). 《Public Health England》 (영어). 2021년 8월 20일. 16 and 22쪽. 2021년 8월 29일에 원본 문서 (PDF)에서 보존된 문서. 2021년 8월 29일에 확인함.
- 《Risk assessment for SARS-CoV-2 variant Omicron》 (PDF) (Assessment). Public Health England. 2021년 12월 22일. GOV-10869. 2021년 12월 23일에 확인함.
sciencemag.org
- Wadman M (2021년 2월 23일). “California coronavirus strain may be more infectious – and lethal”. 《Science News》. doi:10.1126/science.abh2101. 2021년 3월 17일에 확인함.
scmp.com
- “Coronavirus: Sinovac vaccine gives 70 per cent less protection against South African variant, but Hongkongers urged to still get jab”. 《South China Morning Post》. 2021년 4월 20일. 2021년 4월 20일에 확인함.
semanticscholar.org
api.semanticscholar.org
- Coutinho RM, Marquitti FM, Ferreira LS, Borges ME, da Silva RL, Canton O, 외. (2021년 3월 23일). “Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant”. 《medRxiv》 (Preprint): 9. doi:10.1101/2021.03.03.21252706. S2CID 232119656. 2021년 4월 29일에 확인함.
The new variant was found to be about 2.6 times more transmissible (95% Confidence Interval (CI): 2.4–2.8) than previous circulating variant(s). ... Table 1: Summary of the fitted parameters and respective confidence intervals considering the entire period, November 1, 2020-January 31, 2021 maintaining the same pathogenicity of the previous variant. Parameter: Relative transmission rate for the new variant. Estimate: 2.61. 2.5%: 2.45. 97.5%: 2.76.
telegraph.co.uk
- Nuki, Paul; Newey, Sarah (2021년 4월 16일). “Arrival of India's 'double mutation' adds to variant woes, but threat posed remains unclear”. 《The Telegraph》 (영국 영어). ISSN 0307-1235. 2021년 4월 17일에 확인함.
theguardian.com
- Walker, Peter (2021년 6월 6일). “Covid Delta variant ‘about 40% more transmissible’, says Matt Hancock”. 《The Guardian》. 2021년 6월 6일에 확인함.
virological.org
- Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, 외. (2020년 12월 18일). “Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations”. 《Virological》. 2021년 6월 14일에 확인함.
web.archive.org
- “Living Evidence – SARS-CoV-2 variants”. Agency for Clinical Innovation. 《nsw.gov.au》. Ministry of Health (New South Wales). 2021년 4월 16일에 원본 문서에서 보존된 문서. 2021년 3월 22일에 확인함.
- “SARS-CoV-2 variants of concern and variants under investigation in England Technical Briefing 21” (PDF). 《Public Health England》 (영어). 2021년 8월 20일. 16 and 22쪽. 2021년 8월 29일에 원본 문서 (PDF)에서 보존된 문서. 2021년 8월 29일에 확인함.
- Ferguson N, Ghani A, Hinsley W, Volz E (2021년 12월 22일). 《Hospitalisation risk for Omicron cases in England》 (PDF) (기술 보고서). WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis. Imperial College London. doi:10.25561/93035. Report 50. 2021년 12월 23일에 원본 문서에서 보존된 문서.
who.int
- “Tracking SARS-CoV-2 variants”. 《who.int》 (영어). World Health Organization. 2021년 6월 1일에 확인함.
- “Coronavirus Disease (COVID-19) Situation Reports”. 《who.int》. World Health Organization.
- 《Weekly epidemiological update on COVID-19 - 15 June 2021》 (Situation report). World Health Organization. 2021년 6월 15일. 2021년 6월 16일에 확인함.
worldcat.org
- Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DS, Mishra S, 외. (2021년 5월 21일). “Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil”. 《Science》 372 (6544): 815–821. doi:10.1126/science.abh2644. ISSN 0036-8075. PMC 8139423. PMID 33853970.
Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city’s health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
- Nuki, Paul; Newey, Sarah (2021년 4월 16일). “Arrival of India's 'double mutation' adds to variant woes, but threat posed remains unclear”. 《The Telegraph》 (영국 영어). ISSN 0307-1235. 2021년 4월 17일에 확인함.